The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Novo Nordisk stock jumped Wednesday on better-than-expected fourth-quarter sales, helped by an Ozempic beat.

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...